InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
T+90 hit rate
70%
T+90 mean return
+4.1%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Olivo Alicia C, VP Exécutif. Insider active across 1 company, notably Neogenomics INC. Aggregated, 19 reports have been logged. Split: 0 buy · 5 sells. Total volume traded: €187k. Activity tracked since 1 May 2023. The latest transaction was filed on 11 May 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations19 total
3,944 shares0Common StockSEC:0001628280-26-034620
3,944 shares0Common StockSEC:0001628280-26-034620:0
6,503 shares0Common StockSEC:0001077183-25-000106:0
652 shares0Common StockSEC:0001077183-25-000081:0
8,443 shares0Common StockSEC:0001077183-25-000043:0
6,502 shares0Common StockSEC:0001077183-24-000170:0
5,175 shares@ US$15.357540.3% of flowCommon StockSEC:0001077183-24-000162:0
1,666 shares0Common StockSEC:0001077183-24-000146:0
1,040 shares@ US$16.05338.1% of flowCommon StockSEC:0001077183-24-000141:0
14 shares0Common StockSEC:0001077183-24-000112:0
1,049 shares@ US$15.748.1% of flowCommon StockSEC:0001077183-24-000079:0
6,502 shares0Common StockSEC:0001077183-24-000074:0
652 shares0Common StockSEC:0001077183-24-000061:0
2,587 shares@ US$14.964419.3% of flowCommon StockSEC:0001077183-24-000013:0
2,669 shares@ US$18.3924.2% of flowCommon StockSEC:0001077183-23-000140:0
14 shares0Common StockSEC:0001077183-23-000127:0
1,666 shares0Common StockSEC:0001077183-23-000125:0
14 shares0Common StockSEC:0001077183-23-000092:0
662 shares0Common StockSEC:0001077183-23-000032:0
19 of 19 declarations
About Olivo Alicia C
Alicia C. Olivo serves as the EVP, General Counsel & Business Development at Neogenomics Inc. In this role, she oversees the company's legal and business development matters. Her expertise in business law and commercial strategy enables her to contribute to Neogenomics' growth and profitability. She plays a key role in the strategic direction of the company.
